Authors
Latest:
NGS Testing Necessary for Treatment of Lung AdenocarcinomaTimothy F. Burns, MD, PhD, discusses the necessary role of next-generation sequencing testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.
Latest:
Comorbidities, Age, and Outcomes Among Intensively Treated Patients With AMLTimothy S. Pardee, MD, discusses comorbidities, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).
Latest:
What is Lung Suffusion?Todd Demmy, MD, clinical chair, Department of Thoracic Surgery, professor of oncology, Roswell Park Cancer Institute, describes lung suffusion.
Latest:
Measuring Quality and Value With Oncology Pharmacy AccreditationTodd Murphree, PharmD, pharmacist, Clearview Cancer Institute, discusses measuring the quality and value of having oncology pharmacy accreditation.
Latest:
Examining mCRC Chemotherapy Costs, Patient Outcomes in Washington vs British ColumbiaTodd Yezefski, MD, a senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, discusses the results of a trial investigating cost and outcome differences in patients with metastatic colorectal cancer in the United States and Canada. Specifically, he looked at patients in Washington and British Columbia. This data was presented at the 2018 ASCO Annual Meeting.
Latest:
Immune Checkpoint Inhibition in Esophagogastric CancersThe poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody and antagonists of the programmed death (PD)-1/PD-ligand 1 are essential immune checkpoint inhibitors that suppress T-cell activation.
Latest:
Characterization of Immune-Related Adverse Events of Ipilimumab Versus Placebo in mCRPCTomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Latest:
Future Directions for the Treatment of mCRPCTomasz M. Beer, MD, FACP, shares unmet needs and clinical pearls for the management of patients with mCRPC.
Latest:
Researchers Investigate Novel Combinations in Ongoing Trials for RCCToni Choueiri, MD, discusses nivolumab, ipilimumab, and cabozantinib combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma.
Latest:
Closing Thoughts on Data Updates from ASCO 2023 for GU CancersRohit Gosain, MD, and Rahul Gosain, MD, summarize recent key data updates for genitourinary cancers following the 2023 ASCO Annual Meeting.
Latest:
Three of 4 Molecular Subgroups Respond to Dostarlimab in Advanced Endometrial CarcinomaFindings from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial showed that patients with dMMR/MSI-H had a progression-free survival rate of 57.0% in the dostarlimab arm vs 10.2% in the placebo arm.
Latest:
Adding Entinostat to ICI Dual Therapy Delivers Promising Responses in TNBCAlthough immune checkpoint inhibitors have become a cornerstone of therapy across cancer settings, their use in most breast cancer settings has fallen short.
Latest:
Genetic Testing is Essential in NSCLC Prior to Induction TherapyTesting for driver mutations is essential before initiating therapy in patients with non–small cell lung cancer, because there is a risk that the type of upfront treatment chosen could add to the toxicity of, and spur resistance to, targeted therapy options, Suresh S. Ramalingam, MD, said at the 14th Annual New York Lung Cancers Symposium.
Latest:
Dr. Mok Discusses Next Steps With Pembrolizumab in NSCLCTony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.
Latest:
Analyzing the ADAURA Trial of Osimertinib in EGFR+ Lung CancerTony S. K. Mok, BMSc, MD, FRCPC, discusses the ADAURA trial of osimertinib in patients with non–small cell lung cancer.
Latest:
The Challenges of Using Ki67 as a Tool in Breast CancerTorsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.
Latest:
Q & A With Kimberly L. Blackwell: The Treatment of HER2 Metastatic Breast CancerSince its approval in 1998 to treat metastatic disease, trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive breast cancer.
Latest:
Quality of Life as a Predictor of Clinical Outcome in Patients With HNCTrisha Wise-Draper, MD, PhD, assistant professor, University of Cincinnati, discusses the quality of life (QOL) as a predictor of clinical outcome in patients with head and neck cancer (HNC).
Latest:
Dr. Tuya Pal on Genetic Risk Assessment in Ovarian CancerTuya Pal, MD, discusses the importance of genetic risk assessment shaping management guidelines in ovarian cancer.
Latest:
Next Steps for Acalabrutinib in MCLThe results of a phase 1b trial looking at the use of acalabrutinib for patients with treatment-naive or relapsed/refractory mantle cell lymphoma has provided the support needed for the phase 3 ECHO study of this treatment.
Latest:
Updated Response Findings With Larotrectinib in TRK+ CancersUlrik Lassen, MD, PhD, discusses the updated response findings with larotrectinib in TRK+ cancers.
Latest:
Analyzing the Survival Benefits of Niraparib Dose Modification in Ovarian CancerUrsula A. Matulonis, MD, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.
Latest:
An Abundance of PARP Inhibitors are Changing Ovarian Cancer TreatmentUrsula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.
Latest:
Ramucirumab: A Novel Antiangiogenic Agent for Gastric Cancer and Gastroesophageal Junction CancerAdvanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.
Latest:
Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder CancerCisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been the standard of care in muscle-invasive bladder cancer for almost 2 decades. However, the rates of NAC utilization remain low and many patients are ineligible to receive cisplatin due to diminished renal function or other factors. Additionally, there are no reliable biomarkers routinely used in clinical practice that identify patients most likely to benefit from NAC, and limited prospective comparisons of the NAC regimens.
Latest:
Results from a Phase III Trial Analyzing Obinutuzumab (GA101) in CLLValentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.
Latest:
Educating Patients With Melanoma on the Ramifications of Their DiagnosisValerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses educating patients with melanoma on their disease.
Latest:
Pembrolizumab Shows Durable Response in Advanced Unresectable Anal CancerVan K. Morris, MD, discusses the findings of the KEYNOTE-158 trial, which evaluated pembrolizumab in advanced solid tumors in relation to patients with advanced unresectable anal cancer.
Latest:
The Influence of the Gut Microbiome on Response to Anti-PD-1 Therapy in MelanomaVancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator.
